Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Phathom Pharmaceuticals (PHAT) Gross Profit: 2022-2025

Historic Gross Profit for Phathom Pharmaceuticals (PHAT) over the last 4 years, with Sep 2025 value amounting to $43.3 million.

  • Phathom Pharmaceuticals' Gross Profit rose 209.47% to $43.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $128.4 million, marking a year-over-year increase of 485.20%. This contributed to the annual value of $47.3 million for FY2024, which is 9080.39% up from last year.
  • Latest data reveals that Phathom Pharmaceuticals reported Gross Profit of $43.3 million as of Q3 2025, which was up 25.68% from $34.5 million recorded in Q2 2025.
  • Phathom Pharmaceuticals' Gross Profit's 5-year high stood at $43.3 million during Q3 2025, with a 5-year trough of -$10.1 million in Q3 2023.
  • Over the past 3 years, Phathom Pharmaceuticals' median Gross Profit value was $5.9 million (recorded in 2024), while the average stood at $11.0 million.
  • Its Gross Profit has fluctuated over the past 5 years, first slumped by 234.07% in 2023, then spiked by 4,919.22% in 2024.
  • Over the past 4 years, Phathom Pharmaceuticals' Gross Profit (Quarterly) stood at -$9.6 million in 2022, then spiked by 105.36% to $515,000 in 2023, then skyrocketed by 4,919.22% to $25.8 million in 2024, then surged by 209.47% to $43.3 million in 2025.
  • Its Gross Profit was $43.3 million in Q3 2025, compared to $34.5 million in Q2 2025 and $24.8 million in Q1 2025.